Oncogene Inhibitors Therapy Market & Pipeline Insight 2015

がん抑制遺伝子治療の世界市場及びパイプラインインサイト

◆タイトル:Oncogene Inhibitors Therapy Market & Pipeline Insight 2015
◆商品コード:KUICK504091
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年4月
◆ページ数:500
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,400 ⇒換算¥264,000見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD4,800 ⇒換算¥528,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、がん抑制遺伝子治療の世界市場について調査・分析し、がん抑制遺伝子治療の世界市場概要、市場の動態、市場展望、がん抑制遺伝子のパイプライン動向、原癌遺伝子タンパク質の種類別・企業別・フェーズ別パイプライン動向、主要企業分析等の情報をお届けいたします。

Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators.

Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales.

Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria’s set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products.

Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors.

” Oncogene Inhibitors Market & Pipeline Insight 2015″ Report Highlight:

• Global Oncogene Inhibitors Market Overview
• Oncogene Inhibitors Pipeline by Company, Indication & Phase
• Oncogene Inhibitors Pipeline: 185 Drugs
• Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs
• Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs
• Proto Oncogene Protein c-akt Inhibitors: 39 Drugs
• Marketed Oncogene Inhibitors: 22 Drugs
• Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs

【レポートの目次】

1. Introduction to Oncogene Inhibitors

2. Mechanism of Oncogene Inhibitors

3. Global Oncogene Inhibitors Market Overview
3.1 Current Market Scenario
3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. Global Oncogene Inhibitor Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Oncogene Inhibitor Market Future Prospects

6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
6.1 Preclinical
6.2 Suspended & Discontinued

7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase
7.1 Research till Preregistration
7.2 Marketed Drug Clinical Insight
7.3 Suspended & Discontinued

8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase
8.1 Research till Phase-III
8.2 Marketed Drug Clinical Insight
8.3 Suspended & Discontinued

9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase
9.1 Research till Preregistration
9.2 Marketed Drug Clinical Insight
9.3 Suspended & Discontinued

10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase
10.1 Research

11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase
11.1 Preclinical till Phase-III
11.2 Suspended & Discontinued

12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase
12.1 Preclinical till Phase-III
12.2 Marketed Drug Clinical Insight
12.3 Suspended & Discontinued

13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase
13.1 Preclinical till Phase-III
13.2 Marketed Drug Clinical Insight
13.3 Suspended & Discontinued

14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase
14.1 Preclinical till Phase-I/II
14.2 Suspended & Discontinued

15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase
15.1 Preclinical

16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase
16.1 Preclinical

17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase
18.1 Preclinical till Phase-I/II
18.2 Suspended & Discontinued

19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase
19.1 Preclinical till Phase-I/II
19.2 Marketed Drug Clinical Insight

20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase
20.1 Suspended & Discontinued

21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase

22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase
22.1 Preclinical till Registered
22.2 Marketed Drug Clinical Insight
22.3 Suspended & Discontinued

23. Competitive Landscape
23.1 AstraZeneca
23.2 ArQule Inc
23.3 Biogen Idec
23.4 Boehringer Ingelheim
23.5 Celgene Corporation
23.6 Constellation Pharmaceutical
23.7 Epizyme Pharmaceutical
23.8 Genentech
23.9 GalaxoSmithKline
23.10 Incyte Corporation
23.11 Johnson & Johnson
23.12 Merck
23.13 Novartis
23.14 Onyx pharmaceuticals
23.15 Pfizer

Figure 1-1: Features of Oncogenes
Figure 1-2: Types of Genes
Figure 1-3:Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes
Figure 2-1: Activation of Proto-Oncogenes to Oncogenes
Figure 2-2:Benefits of Oncogene Inhibitors
Figure 2-3: Mechanism of Crizotinib
Figure 2-4: Mechanism of Vemurafenib
Figure 2-5: Mechanism of Vorinostat
Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015
Figure 4-1: Oncogene Inhibitor Market Favorable Parameters
Figure 4-2: Commercialization Challenges to Oncogene Inhibitors


Table 3-1: Oncogne Inhibitors Pipeline & Marketed Drugs by Segment

【掲載企業】

AstraZeneca, ArQule Inc, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Constellation Pharmaceutical, Epizyme Pharmaceutical, Genentech
, GalaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck, Novartis, Onyx pharmaceuticals, Pfizer


【レポートのキーワード】

がん抑制遺伝子、がん抑制遺伝子治療、がん原遺伝子、原癌遺伝子タンパク質、パイプライン

★調査レポート[がん抑制遺伝子治療の世界市場及びパイプラインインサイト] ( Oncogene Inhibitors Therapy Market & Pipeline Insight 2015 / KUICK504091) 販売に関する免責事項
[がん抑制遺伝子治療の世界市場及びパイプラインインサイト] ( Oncogene Inhibitors Therapy Market & Pipeline Insight 2015 / KUICK504091) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆